ParkinsonCanadaV1, PascalFrancis, Curation, bibRecord, 000086

Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease : PET evidence of increased dopamine turnover

Identifieur interne : 000086 ( PascalFrancis/Curation ); précédent : 000085; suivant : 000087

Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease : PET evidence of increased dopamine turnover

Auteurs : Raul De La Fuente-Fernandez [Canada] ; Jian-Qiang Lu [Canada] ; Vesna Sossi [Canada] ; Salma Jivan [Canada] ; Michael Schulzer [Canada] ; James E. Holden [États-Unis] ; Chong S. Lee [Canada] ; Thomas J. Ruth [Canada] ; Donald B. Calne [Canada] ; A. Jon Stoessl [Canada]

Source :

Annals of neurology [ 0364-5134 ] ; 2001.

RBID : Pascal:01-0202051

Descripteurs français

Pascal (Inist)
- Parkinson maladie, Dopamine, Raclopride, Tomoscintigraphie, Positon, Toxicité, Trouble motricité, Turnover, Complication, Traitement, Homme, Chimiothérapie, Cardiotonique, Catécholamine, Stimulant dopaminergique, Antagoniste dopamine, Neuroleptique, Psychotrope, Récepteur dopaminergique D2, Lévodopa, Voie orale.
Wicri :
- topic : Homme.

English descriptors

KwdEn :
- Cardiotonic agent, Catecholamine, Chemotherapy, Complication, D2 Dopamine receptor, Dopamine, Dopamine agonist, Dopamine antagonist, Emission tomography, Human, Levodopa, Motility disorder, Neuroleptic, Oral administration, Parkinson disease, Positron, Psychotropic, Raclopride, Toxicity, Treatment, Turnover.

Abstract

Motor fluctuations are a major disabling complication in the treatment of Parkinson's disease. To investigate whether such oscillations in mobility can be attributed to changes in the synaptic levels of dopamine, we studied prospectively patients in the early stages of Parkinson's disease with a follow-up after at least 3 years of levodopa treatment. At baseline, 3 positron emission tomography (PET) scans using [¹¹C]raclopride before and after (1 hour and 4 hours) orally administered levodopa were performed on the same day for each patient. Patients who developed "wearing-off" fluctuations during the follow-up period had a different pattern of levodopa-induced changes in [¹¹C]raclopride binding potential (BP) from that observed in patients who were still stable by the end of the follow-up. Thus, 1 hour post-levodopa the estimated increase in the synaptic level of dopamine was 3 times higher in fluctuators than in stable responders. By contrast, only stable responders maintained increased levels of synaptic dopamine in the PET scan performed after 4 hours. These results indicate that fluctuations in the synaptic concentration of dopamine precede clinically apparent "wearing-off" phenomena. The rapid increase in synaptic levels of dopamine observed in fluctuators suggests that increased dopamine turnover might play a relevant role in levodopa-related motor complications.

A01	`01`	`1`		`@0 0364-5134`
A02	`01`			`@0 ANNED3`
A03		`1`		`@0 Ann. neurol.`
A05				`@2 49`
A06				`@2 3`
A08	`01`	`1`	`ENG`	`@1 Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease : PET evidence of increased dopamine turnover`
A11	`01`	`1`		`@1 DE LA FUENTE-FERNANDEZ (Raul)`
A11	`02`	`1`		`@1 LU (Jian-Qiang)`
A11	`03`	`1`		`@1 SOSSI (Vesna)`
A11	`04`	`1`		`@1 JIVAN (Salma)`
A11	`05`	`1`		`@1 SCHULZER (Michael)`
A11	`06`	`1`		`@1 HOLDEN (James E.)`
A11	`07`	`1`		`@1 LEE (Chong S.)`
A11	`08`	`1`		`@1 RUTH (Thomas J.)`
A11	`09`	`1`		`@1 CALNE (Donald B.)`
A11	`10`	`1`		`@1 STOESSL (A. Jon)`
A14	`01`			`@1 Neurodegenerative Disorders Centre, Vancouver Hospital and Health Sciences Centre @2 Vancouver, BC @3 CAN @Z 1 aut. @Z 2 aut. @Z 5 aut. @Z 7 aut. @Z 9 aut. @Z 10 aut.`
A14	`02`			`@1 TRIUMF, University of British Columbia @2 Vancouver, BC @3 CAN @Z 3 aut. @Z 4 aut. @Z 8 aut.`
A14	`03`			`@1 University of Wisconsin @2 Madison, WI @3 USA @Z 6 aut.`
A20				`@1 298-303`
A21				`@1 2001`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 16555 @5 354000098021420050`
A44				`@0 0000 @1 © 2001 INIST-CNRS. All rights reserved.`
A45				`@0 35 ref.`
A47	`01`	`1`		`@0 01-0202051`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Annals of neurology`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 Motor fluctuations are a major disabling complication in the treatment of Parkinson's disease. To investigate whether such oscillations in mobility can be attributed to changes in the synaptic levels of dopamine, we studied prospectively patients in the early stages of Parkinson's disease with a follow-up after at least 3 years of levodopa treatment. At baseline, 3 positron emission tomography (PET) scans using [¹¹C]raclopride before and after (1 hour and 4 hours) orally administered levodopa were performed on the same day for each patient. Patients who developed "wearing-off" fluctuations during the follow-up period had a different pattern of levodopa-induced changes in [¹¹C]raclopride binding potential (BP) from that observed in patients who were still stable by the end of the follow-up. Thus, 1 hour post-levodopa the estimated increase in the synaptic level of dopamine was 3 times higher in fluctuators than in stable responders. By contrast, only stable responders maintained increased levels of synaptic dopamine in the PET scan performed after 4 hours. These results indicate that fluctuations in the synaptic concentration of dopamine precede clinically apparent "wearing-off" phenomena. The rapid increase in synaptic levels of dopamine observed in fluctuators suggests that increased dopamine turnover might play a relevant role in levodopa-related motor complications.
C02	`01`	`X`		`@0 002B02U01`
C03	`01`	`X`	`FRE`	`@0 Parkinson maladie @5 01`
C03	`01`	`X`	`ENG`	`@0 Parkinson disease @5 01`
C03	`01`	`X`	`SPA`	`@0 Parkinson enfermedad @5 01`
C03	`02`	`X`	`FRE`	`@0 Dopamine @2 NK @2 FR @5 02`
C03	`02`	`X`	`ENG`	`@0 Dopamine @2 NK @2 FR @5 02`
C03	`02`	`X`	`SPA`	`@0 Dopamina @2 NK @2 FR @5 02`
C03	`03`	`X`	`FRE`	`@0 Raclopride @2 NK @2 FR @5 05`
C03	`03`	`X`	`ENG`	`@0 Raclopride @2 NK @2 FR @5 05`
C03	`03`	`X`	`SPA`	`@0 Racloprida @2 NK @2 FR @5 05`
C03	`04`	`X`	`FRE`	`@0 Tomoscintigraphie @5 13`
C03	`04`	`X`	`ENG`	`@0 Emission tomography @5 13`
C03	`04`	`X`	`SPA`	`@0 Tomocentelleografía @5 13`
C03	`05`	`X`	`FRE`	`@0 Positon @5 14`
C03	`05`	`X`	`ENG`	`@0 Positron @5 14`
C03	`05`	`X`	`SPA`	`@0 Positrón @5 14`
C03	`06`	`X`	`FRE`	`@0 Toxicité @5 16`
C03	`06`	`X`	`ENG`	`@0 Toxicity @5 16`
C03	`06`	`X`	`SPA`	`@0 Toxicidad @5 16`
C03	`07`	`X`	`FRE`	`@0 Trouble motricité @5 17`
C03	`07`	`X`	`ENG`	`@0 Motility disorder @5 17`
C03	`07`	`X`	`SPA`	`@0 Trastorno motilidad @5 17`
C03	`08`	`X`	`FRE`	`@0 Turnover @5 20`
C03	`08`	`X`	`ENG`	`@0 Turnover @5 20`
C03	`08`	`X`	`SPA`	`@0 Turnover @5 20`
C03	`09`	`X`	`FRE`	`@0 Complication @5 21`
C03	`09`	`X`	`ENG`	`@0 Complication @5 21`
C03	`09`	`X`	`SPA`	`@0 Complicación @5 21`
C03	`10`	`X`	`FRE`	`@0 Traitement @5 22`
C03	`10`	`X`	`ENG`	`@0 Treatment @5 22`
C03	`10`	`X`	`SPA`	`@0 Tratamiento @5 22`
C03	`11`	`X`	`FRE`	`@0 Homme @5 23`
C03	`11`	`X`	`ENG`	`@0 Human @5 23`
C03	`11`	`X`	`SPA`	`@0 Hombre @5 23`
C03	`12`	`X`	`FRE`	`@0 Chimiothérapie @5 24`
C03	`12`	`X`	`ENG`	`@0 Chemotherapy @5 24`
C03	`12`	`X`	`SPA`	`@0 Quimioterapia @5 24`
C03	`13`	`X`	`FRE`	`@0 Cardiotonique @5 25`
C03	`13`	`X`	`ENG`	`@0 Cardiotonic agent @5 25`
C03	`13`	`X`	`SPA`	`@0 Cardiotónico @5 25`
C03	`14`	`X`	`FRE`	`@0 Catécholamine @5 26`
C03	`14`	`X`	`ENG`	`@0 Catecholamine @5 26`
C03	`14`	`X`	`SPA`	`@0 Catecolamina @5 26`
C03	`15`	`X`	`FRE`	`@0 Stimulant dopaminergique @5 27`
C03	`15`	`X`	`ENG`	`@0 Dopamine agonist @5 27`
C03	`15`	`X`	`SPA`	`@0 Estimulante dopaminérgico @5 27`
C03	`16`	`X`	`FRE`	`@0 Antagoniste dopamine @5 28`
C03	`16`	`X`	`ENG`	`@0 Dopamine antagonist @5 28`
C03	`16`	`X`	`SPA`	`@0 Antagonista dopamina @5 28`
C03	`17`	`X`	`FRE`	`@0 Neuroleptique @5 29`
C03	`17`	`X`	`ENG`	`@0 Neuroleptic @5 29`
C03	`17`	`X`	`SPA`	`@0 Neuroléptico @5 29`
C03	`18`	`X`	`FRE`	`@0 Psychotrope @2 FX @5 30`
C03	`18`	`X`	`ENG`	`@0 Psychotropic @2 FX @5 30`
C03	`18`	`X`	`SPA`	`@0 Psicotropo @2 FX @5 30`
C03	`19`	`X`	`FRE`	`@0 Récepteur dopaminergique D2 @5 31`
C03	`19`	`X`	`ENG`	`@0 D2 Dopamine receptor @5 31 @6 «D2» Dopamine receptor`
C03	`19`	`X`	`SPA`	`@0 Receptor dopaminérgico D2 @5 31`
C03	`20`	`X`	`FRE`	`@0 Lévodopa @5 35`
C03	`20`	`X`	`ENG`	`@0 Levodopa @5 35`
C03	`20`	`X`	`SPA`	`@0 Levodopa @5 35`
C03	`21`	`X`	`FRE`	`@0 Voie orale @5 36`
C03	`21`	`X`	`ENG`	`@0 Oral administration @5 36`
C03	`21`	`X`	`SPA`	`@0 Vía oral @5 36`
C07	`01`	`X`	`FRE`	`@0 Système nerveux pathologie @5 37`
C07	`01`	`X`	`ENG`	`@0 Nervous system diseases @5 37`
C07	`01`	`X`	`SPA`	`@0 Sistema nervioso patología @5 37`
C07	`02`	`X`	`FRE`	`@0 Système nerveux central pathologie @5 38`
C07	`02`	`X`	`ENG`	`@0 Central nervous system disease @5 38`
C07	`02`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 38`
C07	`03`	`X`	`FRE`	`@0 Maladie dégénérative @5 39`
C07	`03`	`X`	`ENG`	`@0 Degenerative disease @5 39`
C07	`03`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 39`
C07	`04`	`X`	`FRE`	`@0 Extrapyramidal syndrome @5 40`
C07	`04`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 40`
C07	`04`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 40`
C07	`05`	`X`	`FRE`	`@0 Encéphale pathologie @5 41`
C07	`05`	`X`	`ENG`	`@0 Cerebral disorder @5 41`
C07	`05`	`X`	`SPA`	`@0 Encéfalo patología @5 41`
C07	`06`	`X`	`FRE`	`@0 Exploration radioisotopique @5 69`
C07	`06`	`X`	`ENG`	`@0 Radionuclide study @5 69`
C07	`06`	`X`	`SPA`	`@0 Exploración radioisotópica @5 69`
N21				`@1 141`

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000C37

Links to Exploration step

Pascal:01-0202051

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease : PET evidence of increased dopamine turnover</title>
<author><name sortKey="De La Fuente Fernandez, Raul" sort="De La Fuente Fernandez, Raul" uniqKey="De La Fuente Fernandez R" first="Raul" last="De La Fuente-Fernandez">Raul De La Fuente-Fernandez</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Neurodegenerative Disorders Centre, Vancouver Hospital and Health Sciences Centre</s1>
<s2>Vancouver, BC</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Lu, Jian Qiang" sort="Lu, Jian Qiang" uniqKey="Lu J" first="Jian-Qiang" last="Lu">Jian-Qiang Lu</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Neurodegenerative Disorders Centre, Vancouver Hospital and Health Sciences Centre</s1>
<s2>Vancouver, BC</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Sossi, Vesna" sort="Sossi, Vesna" uniqKey="Sossi V" first="Vesna" last="Sossi">Vesna Sossi</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>TRIUMF, University of British Columbia</s1>
<s2> Vancouver, BC</s2>
<s3>CAN</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Jivan, Salma" sort="Jivan, Salma" uniqKey="Jivan S" first="Salma" last="Jivan">Salma Jivan</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>TRIUMF, University of British Columbia</s1>
<s2> Vancouver, BC</s2>
<s3>CAN</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Schulzer, Michael" sort="Schulzer, Michael" uniqKey="Schulzer M" first="Michael" last="Schulzer">Michael Schulzer</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Neurodegenerative Disorders Centre, Vancouver Hospital and Health Sciences Centre</s1>
<s2>Vancouver, BC</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Holden, James E" sort="Holden, James E" uniqKey="Holden J" first="James E." last="Holden">James E. Holden</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>University of Wisconsin</s1>
<s2>Madison, WI</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Lee, Chong S" sort="Lee, Chong S" uniqKey="Lee C" first="Chong S." last="Lee">Chong S. Lee</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Neurodegenerative Disorders Centre, Vancouver Hospital and Health Sciences Centre</s1>
<s2>Vancouver, BC</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Ruth, Thomas J" sort="Ruth, Thomas J" uniqKey="Ruth T" first="Thomas J." last="Ruth">Thomas J. Ruth</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>TRIUMF, University of British Columbia</s1>
<s2> Vancouver, BC</s2>
<s3>CAN</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Calne, Donald B" sort="Calne, Donald B" uniqKey="Calne D" first="Donald B." last="Calne">Donald B. Calne</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Neurodegenerative Disorders Centre, Vancouver Hospital and Health Sciences Centre</s1>
<s2>Vancouver, BC</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Stoessl, A Jon" sort="Stoessl, A Jon" uniqKey="Stoessl A" first="A. Jon" last="Stoessl">A. Jon Stoessl</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Neurodegenerative Disorders Centre, Vancouver Hospital and Health Sciences Centre</s1>
<s2>Vancouver, BC</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">01-0202051</idno>
<date when="2001">2001</date>
<idno type="stanalyst">PASCAL 01-0202051 INIST</idno>
<idno type="RBID">Pascal:01-0202051</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000C37</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000086</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease : PET evidence of increased dopamine turnover</title>
<author><name sortKey="De La Fuente Fernandez, Raul" sort="De La Fuente Fernandez, Raul" uniqKey="De La Fuente Fernandez R" first="Raul" last="De La Fuente-Fernandez">Raul De La Fuente-Fernandez</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Neurodegenerative Disorders Centre, Vancouver Hospital and Health Sciences Centre</s1>
<s2>Vancouver, BC</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Lu, Jian Qiang" sort="Lu, Jian Qiang" uniqKey="Lu J" first="Jian-Qiang" last="Lu">Jian-Qiang Lu</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Neurodegenerative Disorders Centre, Vancouver Hospital and Health Sciences Centre</s1>
<s2>Vancouver, BC</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Sossi, Vesna" sort="Sossi, Vesna" uniqKey="Sossi V" first="Vesna" last="Sossi">Vesna Sossi</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>TRIUMF, University of British Columbia</s1>
<s2> Vancouver, BC</s2>
<s3>CAN</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Jivan, Salma" sort="Jivan, Salma" uniqKey="Jivan S" first="Salma" last="Jivan">Salma Jivan</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>TRIUMF, University of British Columbia</s1>
<s2> Vancouver, BC</s2>
<s3>CAN</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Schulzer, Michael" sort="Schulzer, Michael" uniqKey="Schulzer M" first="Michael" last="Schulzer">Michael Schulzer</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Neurodegenerative Disorders Centre, Vancouver Hospital and Health Sciences Centre</s1>
<s2>Vancouver, BC</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Holden, James E" sort="Holden, James E" uniqKey="Holden J" first="James E." last="Holden">James E. Holden</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>University of Wisconsin</s1>
<s2>Madison, WI</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Lee, Chong S" sort="Lee, Chong S" uniqKey="Lee C" first="Chong S." last="Lee">Chong S. Lee</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Neurodegenerative Disorders Centre, Vancouver Hospital and Health Sciences Centre</s1>
<s2>Vancouver, BC</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Ruth, Thomas J" sort="Ruth, Thomas J" uniqKey="Ruth T" first="Thomas J." last="Ruth">Thomas J. Ruth</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>TRIUMF, University of British Columbia</s1>
<s2> Vancouver, BC</s2>
<s3>CAN</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Calne, Donald B" sort="Calne, Donald B" uniqKey="Calne D" first="Donald B." last="Calne">Donald B. Calne</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Neurodegenerative Disorders Centre, Vancouver Hospital and Health Sciences Centre</s1>
<s2>Vancouver, BC</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Stoessl, A Jon" sort="Stoessl, A Jon" uniqKey="Stoessl A" first="A. Jon" last="Stoessl">A. Jon Stoessl</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Neurodegenerative Disorders Centre, Vancouver Hospital and Health Sciences Centre</s1>
<s2>Vancouver, BC</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Annals of neurology</title>
<title level="j" type="abbreviated">Ann. neurol.</title>
<idno type="ISSN">0364-5134</idno>
<imprint><date when="2001">2001</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Annals of neurology</title>
<title level="j" type="abbreviated">Ann. neurol.</title>
<idno type="ISSN">0364-5134</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Cardiotonic agent</term>
<term>Catecholamine</term>
<term>Chemotherapy</term>
<term>Complication</term>
<term>D2 Dopamine receptor</term>
<term>Dopamine</term>
<term>Dopamine agonist</term>
<term>Dopamine antagonist</term>
<term>Emission tomography</term>
<term>Human</term>
<term>Levodopa</term>
<term>Motility disorder</term>
<term>Neuroleptic</term>
<term>Oral administration</term>
<term>Parkinson disease</term>
<term>Positron</term>
<term>Psychotropic</term>
<term>Raclopride</term>
<term>Toxicity</term>
<term>Treatment</term>
<term>Turnover</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Parkinson maladie</term>
<term>Dopamine</term>
<term>Raclopride</term>
<term>Tomoscintigraphie</term>
<term>Positon</term>
<term>Toxicité</term>
<term>Trouble motricité</term>
<term>Turnover</term>
<term>Complication</term>
<term>Traitement</term>
<term>Homme</term>
<term>Chimiothérapie</term>
<term>Cardiotonique</term>
<term>Catécholamine</term>
<term>Stimulant dopaminergique</term>
<term>Antagoniste dopamine</term>
<term>Neuroleptique</term>
<term>Psychotrope</term>
<term>Récepteur dopaminergique D2</term>
<term>Lévodopa</term>
<term>Voie orale</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Motor fluctuations are a major disabling complication in the treatment of Parkinson's disease. To investigate whether such oscillations in mobility can be attributed to changes in the synaptic levels of dopamine, we studied prospectively patients in the early stages of Parkinson's disease with a follow-up after at least 3 years of levodopa treatment. At baseline, 3 positron emission tomography (PET) scans using [<sup>11</sup>
C]raclopride before and after (1 hour and 4 hours) orally administered levodopa were performed on the same day for each patient. Patients who developed "wearing-off" fluctuations during the follow-up period had a different pattern of levodopa-induced changes in [<sup>11</sup>
C]raclopride binding potential (BP) from that observed in patients who were still stable by the end of the follow-up. Thus, 1 hour post-levodopa the estimated increase in the synaptic level of dopamine was 3 times higher in fluctuators than in stable responders. By contrast, only stable responders maintained increased levels of synaptic dopamine in the PET scan performed after 4 hours. These results indicate that fluctuations in the synaptic concentration of dopamine precede clinically apparent "wearing-off" phenomena. The rapid increase in synaptic levels of dopamine observed in fluctuators suggests that increased dopamine turnover might play a relevant role in levodopa-related motor complications.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0364-5134</s0>
</fA01>
<fA02 i1="01"><s0>ANNED3</s0>
</fA02>
<fA03 i2="1"><s0>Ann. neurol.</s0>
</fA03>
<fA05><s2>49</s2>
</fA05>
<fA06><s2>3</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease : PET evidence of increased dopamine turnover</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>DE LA FUENTE-FERNANDEZ (Raul)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>LU (Jian-Qiang)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>SOSSI (Vesna)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>JIVAN (Salma)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>SCHULZER (Michael)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>HOLDEN (James E.)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>LEE (Chong S.)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>RUTH (Thomas J.)</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>CALNE (Donald B.)</s1>
</fA11>
<fA11 i1="10" i2="1"><s1>STOESSL (A. Jon)</s1>
</fA11>
<fA14 i1="01"><s1>Neurodegenerative Disorders Centre, Vancouver Hospital and Health Sciences Centre</s1>
<s2>Vancouver, BC</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>TRIUMF, University of British Columbia</s1>
<s2> Vancouver, BC</s2>
<s3>CAN</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>8 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>University of Wisconsin</s1>
<s2>Madison, WI</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
</fA14>
<fA20><s1>298-303</s1>
</fA20>
<fA21><s1>2001</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>16555</s2>
<s5>354000098021420050</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2001 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>35 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>01-0202051</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Annals of neurology</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Motor fluctuations are a major disabling complication in the treatment of Parkinson's disease. To investigate whether such oscillations in mobility can be attributed to changes in the synaptic levels of dopamine, we studied prospectively patients in the early stages of Parkinson's disease with a follow-up after at least 3 years of levodopa treatment. At baseline, 3 positron emission tomography (PET) scans using [<sup>11</sup>
C]raclopride before and after (1 hour and 4 hours) orally administered levodopa were performed on the same day for each patient. Patients who developed "wearing-off" fluctuations during the follow-up period had a different pattern of levodopa-induced changes in [<sup>11</sup>
C]raclopride binding potential (BP) from that observed in patients who were still stable by the end of the follow-up. Thus, 1 hour post-levodopa the estimated increase in the synaptic level of dopamine was 3 times higher in fluctuators than in stable responders. By contrast, only stable responders maintained increased levels of synaptic dopamine in the PET scan performed after 4 hours. These results indicate that fluctuations in the synaptic concentration of dopamine precede clinically apparent "wearing-off" phenomena. The rapid increase in synaptic levels of dopamine observed in fluctuators suggests that increased dopamine turnover might play a relevant role in levodopa-related motor complications.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B02U01</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Parkinson maladie</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Dopamine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Dopamine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Dopamina</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Raclopride</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>05</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Raclopride</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>05</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Racloprida</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>05</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Tomoscintigraphie</s0>
<s5>13</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Emission tomography</s0>
<s5>13</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Tomocentelleografía</s0>
<s5>13</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Positon</s0>
<s5>14</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Positron</s0>
<s5>14</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Positrón</s0>
<s5>14</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Toxicité</s0>
<s5>16</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Toxicity</s0>
<s5>16</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Toxicidad</s0>
<s5>16</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Trouble motricité</s0>
<s5>17</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Motility disorder</s0>
<s5>17</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Trastorno motilidad</s0>
<s5>17</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Turnover</s0>
<s5>20</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Turnover</s0>
<s5>20</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Turnover</s0>
<s5>20</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Complication</s0>
<s5>21</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Complication</s0>
<s5>21</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Complicación</s0>
<s5>21</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Traitement</s0>
<s5>22</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Treatment</s0>
<s5>22</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Tratamiento</s0>
<s5>22</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Homme</s0>
<s5>23</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Human</s0>
<s5>23</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Hombre</s0>
<s5>23</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE"><s0>Chimiothérapie</s0>
<s5>24</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG"><s0>Chemotherapy</s0>
<s5>24</s5>
</fC03>
<fC03 i1="12" i2="X" l="SPA"><s0>Quimioterapia</s0>
<s5>24</s5>
</fC03>
<fC03 i1="13" i2="X" l="FRE"><s0>Cardiotonique</s0>
<s5>25</s5>
</fC03>
<fC03 i1="13" i2="X" l="ENG"><s0>Cardiotonic agent</s0>
<s5>25</s5>
</fC03>
<fC03 i1="13" i2="X" l="SPA"><s0>Cardiotónico</s0>
<s5>25</s5>
</fC03>
<fC03 i1="14" i2="X" l="FRE"><s0>Catécholamine</s0>
<s5>26</s5>
</fC03>
<fC03 i1="14" i2="X" l="ENG"><s0>Catecholamine</s0>
<s5>26</s5>
</fC03>
<fC03 i1="14" i2="X" l="SPA"><s0>Catecolamina</s0>
<s5>26</s5>
</fC03>
<fC03 i1="15" i2="X" l="FRE"><s0>Stimulant dopaminergique</s0>
<s5>27</s5>
</fC03>
<fC03 i1="15" i2="X" l="ENG"><s0>Dopamine agonist</s0>
<s5>27</s5>
</fC03>
<fC03 i1="15" i2="X" l="SPA"><s0>Estimulante dopaminérgico</s0>
<s5>27</s5>
</fC03>
<fC03 i1="16" i2="X" l="FRE"><s0>Antagoniste dopamine</s0>
<s5>28</s5>
</fC03>
<fC03 i1="16" i2="X" l="ENG"><s0>Dopamine antagonist</s0>
<s5>28</s5>
</fC03>
<fC03 i1="16" i2="X" l="SPA"><s0>Antagonista dopamina</s0>
<s5>28</s5>
</fC03>
<fC03 i1="17" i2="X" l="FRE"><s0>Neuroleptique</s0>
<s5>29</s5>
</fC03>
<fC03 i1="17" i2="X" l="ENG"><s0>Neuroleptic</s0>
<s5>29</s5>
</fC03>
<fC03 i1="17" i2="X" l="SPA"><s0>Neuroléptico</s0>
<s5>29</s5>
</fC03>
<fC03 i1="18" i2="X" l="FRE"><s0>Psychotrope</s0>
<s2>FX</s2>
<s5>30</s5>
</fC03>
<fC03 i1="18" i2="X" l="ENG"><s0>Psychotropic</s0>
<s2>FX</s2>
<s5>30</s5>
</fC03>
<fC03 i1="18" i2="X" l="SPA"><s0>Psicotropo</s0>
<s2>FX</s2>
<s5>30</s5>
</fC03>
<fC03 i1="19" i2="X" l="FRE"><s0>Récepteur dopaminergique D2</s0>
<s5>31</s5>
</fC03>
<fC03 i1="19" i2="X" l="ENG"><s0>D2 Dopamine receptor</s0>
<s5>31</s5>
<s6>«D2» Dopamine receptor</s6>
</fC03>
<fC03 i1="19" i2="X" l="SPA"><s0>Receptor dopaminérgico D2</s0>
<s5>31</s5>
</fC03>
<fC03 i1="20" i2="X" l="FRE"><s0>Lévodopa</s0>
<s5>35</s5>
</fC03>
<fC03 i1="20" i2="X" l="ENG"><s0>Levodopa</s0>
<s5>35</s5>
</fC03>
<fC03 i1="20" i2="X" l="SPA"><s0>Levodopa</s0>
<s5>35</s5>
</fC03>
<fC03 i1="21" i2="X" l="FRE"><s0>Voie orale</s0>
<s5>36</s5>
</fC03>
<fC03 i1="21" i2="X" l="ENG"><s0>Oral administration</s0>
<s5>36</s5>
</fC03>
<fC03 i1="21" i2="X" l="SPA"><s0>Vía oral</s0>
<s5>36</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Encéphale pathologie</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>41</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Exploration radioisotopique</s0>
<s5>69</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Radionuclide study</s0>
<s5>69</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Exploración radioisotópica</s0>
<s5>69</s5>
</fC07>
<fN21><s1>141</s1>
</fN21>
</pA>
</standard>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PascalFrancis/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000086 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 000086 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    PascalFrancis
   |étape=   Curation
   |type=    RBID
   |clé=     Pascal:01-0202051
   |texte=   Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease : PET evidence of increased dopamine turnover
}}

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022

	La maladie de Parkinson au Canada (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

La maladie de Parkinson au Canada (serveur d'exploration)

Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease : PET evidence of increased dopamine turnover

Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease : PET evidence of increased dopamine turnover

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri